CongL, RanFA, CoxD, et al.Multiplex Genome Engineering Using CRISPR/Cas Systems. Science, 2013; 339(6121): 819–823.
2.
ShalemO, SanjanaNE, HartenianE, et al.Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science, 2014; 343(6166): 84–87.
3.
OrchardRC, WilenCB, DoenchJG, et al.Discovery of a proteinaceous cellular receptor for a norovirus. Science, 2016; 353(6302): 933–936.
4.
CanverMC, SmithEC, SherF, et al.BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015; 527: 192–197.
5.
ZipkinM. CRISPR's “magnificent moment” in the clinic. Nature Biotechnol. News 06Dec.2019; DOI: 10.1038/d41587-019-00035-2.
6.
NajmFJ, StrandC, DonovanKF, et al.Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens. Nature Biotechnol. 2018; 36: 179–189.
7.
SansonKR, DeWeirdtPC, SangreeAK, et al.Optimization of AsCas12a for combinatorial genetic screens in human cells. bioRxiv, 2019; DOI: 10.1101/747170.
8.
TianR, GachechiladzeMA, LudwigCH, et al.CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons. Neuron, 2019; 104(2): 239–255.e12.
9.
ChenS, SanjanaNE, ZhengK, et al.Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis. Cell, 2015; 160(6): 1246–1260.
10.
ChowRD, GuzmanCD, WangG, et al.AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nature Neurosci. 2017; 20: 1329–1341.
